# Cisplatin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cisplatin

> The FDA approved cisplatin, sponsored by FENNEC PHARMACEUTICALS INC. (FENC), on September 20, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is cisplatin FDA approved?

Yes. The FDA approved cisplatin, sponsored by FENNEC PHARMACEUTICALS INC. (FENC), on September 20, 2022. SEC prospectus (424B): "On September 20, 2022 we received approval from the U.S. Food and Drug Administration ("FDA") for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." [Calendar and source filings](https://sec-api.dev/pdufa/cisplatin)

Source: SEC prospectus (424B), accession 0001104659-25-113422, https://www.sec.gov/Archives/edgar/data/1211583/000110465925113422/tm2531484-1_424b5.htm (retrieved 2026-11-12). Last confirmed 2025-11-18. Cite: https://sec-api.dev/pdufa/cisplatin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | cisplatin |
| Codes | DMS32212R, ABC-08 |
| Sponsor | FENNEC PHARMACEUTICALS INC. (FENC) https://sec-api.dev/companies/fenc/catalysts |
| Indications | cisplatin-ineligible head and neck cancer |
| Modality |  |
| FDA designations | accelerated, priority review |

## Timeline

### Mar 2022: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-27, last confirmed 2025-11-17.
- SEC Form 10-Q (accession 0001493152-25-023894): "In fact, in March 2022 we announced interim data from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist)" https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm
- SEC Form 10-Q (accession 0001493152-25-011986): "In fact, in March 2022 we announced interim data from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist)" https://www.sec.gov/Archives/edgar/data/946644/000149315225011986/form10-q.htm
- SEC Form 10-Q (accession 0001641172-25-011033): "In fact, in March 2022 we announced interim data from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist)" https://www.sec.gov/Archives/edgar/data/946644/000164117225011033/form10-q.htm
- SEC Form 10-K (accession 0001641172-25-000847): "In fact, in March 2022 we announced interim data from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist)" https://www.sec.gov/Archives/edgar/data/946644/000164117225000847/form10-k.htm

### September 20, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-26, last confirmed 2025-11-18.
- SEC prospectus (424B) (accession 0001104659-25-113422): "On September 20, 2022 we received approval from the U.S. Food and Drug Administration ("FDA") for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000110465925113422/tm2531484-1_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-113422): "On September 20, 2022, we received approval from the U.S. Food and Drug Administration ("FDA") for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000110465925113422/tm2531484-1_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-112916): "On September 20, 2022 we received approval from the U.S. Food and Drug Administration ("FDA") for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000110465925112916/tm2531139-2_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-112916): "On September 20, 2022, we received approval from the U.S. Food and Drug Administration ("FDA") for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000110465925112916/tm2531139-2_424b5.htm
- SEC Form 10-Q (accession 0001104659-25-111260): "On September 20, 2022, we received approval from the FDA for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000110465925111260/fencf-20250930x10q.htm
- SEC prospectus (424B) (accession 0001104659-25-111305): "On September 20, 2022, we received approval from the U.S. Food and Drug Administration ("FDA") for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000110465925111305/tm2531139d1_424b5.htm
- SEC Form 10-Q (accession 0001558370-25-011552): "On September 20, 2022, we received approval from the FDA for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000155837025011552/fencf-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007748): "On September 20, 2022, we received approval from the FDA for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000155837025007748/fencf-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003710): "On September 20, 2022, we received approval from the FDA for PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm

### June 23, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-04-24, last confirmed 2025-05-02.
- SEC Form 10-Q (accession 0001628280-25-021834): "The FDA set a PDUFA date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-038301): "The FDA has set a PDUFA date of June 23, 2025." https://www.sec.gov/Archives/edgar/data/310158/000110465925038301/tm2512885d1_ex99-1.htm

### December 2, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2/3.
- First seen 2025-12-02, last confirmed 2026-11-12.
- SEC Form 8-K (accession 0001104659-25-117697): "On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_8k.htm
- SEC Form 10-Q (accession 0001104659-26-126203): "In December 2025, we announced positive topline results from this trial that demonstrated use of PEDMARK® was associated with a significant reduction in the incidence of hearing loss compared to historically reported rates in patients receiving cisplatin alone, with no evidence of reduced antitumor activity and an approximate 95% clinical response rate." https://www.sec.gov/Archives/edgar/data/1211583/000110465926126203/fencf-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095884): "In December 2025, we announced positive topline results from this trial that demonstrated use of PEDMARK® was associated with a significant reduction in the incidence of hearing loss compared to historically reported rates in patients receiving cisplatin alone, with no evidence of reduced antitumor activity and an approximate 95% clinical response rate." https://www.sec.gov/Archives/edgar/data/1211583/000110465926095884/fencf-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061213): "In December 2025, we announced positive topline results from this trial that demonstrated use of PEDMARK® was associated with a significant reduction in the incidence of hearing loss compared to historically reported rates in patients receiving cisplatin alone, with no evidence of reduced antitumor activity and an approximate 95% clinical response rate." https://www.sec.gov/Archives/edgar/data/1211583/000110465926061213/fencf-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-036182): "In December 2025, we announced positive topline results from this trial that demonstrated use of PEDMARK® was associated with a significant reduction in the incidence of hearing loss compared to historically reported rates in patients receiving cisplatin alone, with no evidence of reduced antitumor activity and an approximate 95% clinical response rate." https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/fencf-20251231x10k.htm

### December 2, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2/3.
- First seen 2025-12-02, last confirmed 2025-12-02.
- SEC Form 8-K (accession 0001104659-25-117697): "On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_8k.htm

### March 24, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2/3.
- First seen 2026-03-24, last confirmed 2026-03-24.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-033885): "STS-J01 in Japan: In December, Fennec announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324xex99d1.htm

### Jun 2026: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: cisplatin-ineligible head and neck cancer.
- First seen 2026-10-29, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-113564): "In June 2026, an investigator-initiated Phase II trial of Promitil® with radiotherapy in patients with cisplatin-ineligible head and neck cancer was launched in Israel." https://www.sec.gov/Archives/edgar/data/1713863/000121390026113564/ea030996101ex99-1.htm

### August 17, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3.
- First seen 2026-04-30, last confirmed 2026-05-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-052081): "§ FDA set PDUFA date of Aug. 17, 2026." https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-052081): "From Phase 3 KEYNOTE-B15 Trial; FDA Set PDUFA Date of Aug. 17, 2026" https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm
- SEC Form 10-Q (accession 0001628280-26-029802): "The FDA set a PDUFA date of August 17, 2026." https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm

### August 17, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-05-05, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0000078003-26-000053): "The FDA has set a PDUFA target action date of August 17, 2026." https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm

### September 17, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-09-17, last confirmed 2026-09-17.
- SEC Form 8-K (accession 0001104659-26-108565): "On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity." https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-108565): "Research Triangle Park, NC, September 17, 2026 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917xex99d1.htm

Calendar months: [June 2025](https://sec-api.dev/fda-calendar/2025-06), [August 2026](https://sec-api.dev/fda-calendar/2026-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cisplatin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cisplatin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cisplatin

```bibtex
@misc{secapidev_pdufa_cisplatin_20261116,
  title        = {Cisplatin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cisplatin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cisplatin_20261116","title":"Cisplatin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cisplatin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
